David Stevenson's Adventurous Investor Newsletter

David Stevenson's Adventurous Investor Newsletter

Share this post

David Stevenson's Adventurous Investor Newsletter
David Stevenson's Adventurous Investor Newsletter
Investment Ideas: Biopharma Credit, avoiding China, and a cash idea from Killik for higher rate tax payers

Investment Ideas: Biopharma Credit, avoiding China, and a cash idea from Killik for higher rate tax payers

Assuming you are cautious (I am), its best to play safe which is why I lending fund Biopharma Credit is attractive. Also excellent summary from Schroders on why you need to avoid China

David Stevenson's avatar
David Stevenson
Sep 21, 2022
∙ Paid
2

Share this post

David Stevenson's Adventurous Investor Newsletter
David Stevenson's Adventurous Investor Newsletter
Investment Ideas: Biopharma Credit, avoiding China, and a cash idea from Killik for higher rate tax payers
Share

Share

Buy Biopharma Credit

So, regulars will know that I am cautious about markets and believe that we are due another leg down in US equities. I’m reluctant to recommend buying very much at the moment but I am going to don my adventurous mantle and suggest that a one-year bet on a UK-listed lending fund called Biopharma Credit might be worth it.

To recap, list…

Keep reading with a 7-day free trial

Subscribe to David Stevenson's Adventurous Investor Newsletter to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 David Stevenson
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share